1. McHowat, J., Swift, L. M., Arutunyan, A., & Sarvazyan, N. (2001). Clinical concentrations of doxorubicin inhibit activity of myocardial membrane-associated, calcium-independent phospholipase A(2). Cancer Research, 61, 4024–4029.
2. McHowat, J., Swift, L. M., & Sarvazyan, N. (2001). Oxidant-induced inhibition of myocardial calcium-independent phospholipase A2. Cardiovascular Toxicology, 1, 309–316.
3. Swift, L., McHowat, J., & Sarvazyan, N. (2003). Inhibition of Membrane-associated Calcium-independent Phospholipase A2 as a Potential Culprit of Anthracycline Cardiotoxicity. Cancer Research, 63, 5992–5998.
4. McHowat, J., Swift, L. M., Crown, K. N., & Sarvazyan, N. A. (2004). Changes in phospholipid content and myocardial calcium-independent phospholipase A2 activity during chronic anthracycline administration. The Journal of Pharmacology and Experimental Therapeutics, 311, 736–741.
5. Sarvazyan, N. A., Askari, A., & Huang, W. H. (1995). Effects of doxorubicin on cardiomyocytes with reduced level of superoxide dismutase. Life Science, 57, 1003–1010.